微导管超选技术治疗原发性肝癌的临床应用

摘要

目的：探讨微导管超选技术治疗原发性肝癌的应用价值。方法选择已确诊为原发性肝癌患者100例，随机分为超选栓塞组50例和普通栓塞组50例。普通栓塞组常规采用5F RH 导管或5F YASINO导管行超选择栓塞治疗，微导管栓塞组采用SP 3 F同轴微导管作超选肝段或者亚肝段的肿瘤供血血管栓塞治疗，并观察疗效和不良反应。结果治疗后4周，超选栓塞组肿瘤体积缩小总有效率为80％，普通栓塞组肿瘤体积缩小总有效率为72％，两组比较差异无显著性（P＞0．05）；而超选栓塞组治疗后AFP值低于普通栓塞组（P＜0．05），差异有统计学意义；在不良反应方面，超选栓塞组的肝功能损害较普通栓塞组轻，差异有统计学意义（ P＜0．05）。结论微导管超选技术治疗原发性肝癌疗效好，不良反应轻，在临床上值得推广应用。%Objective To explore the value of microcatheter superseletive catheterization therapy for primary liver canc-er.Methods 100 cases of primary liver cancer were randomly divided of into conventional embolization therapy group( group A) and microcatheter embolization therapy group (group B),each with 50 cases.T RH catheter or YASINO catheter were used in group A.Superselective liver segmental or liver subsegmental tumor feeding artory to embolize with SP 3F coaxial microcatheter were used in Group B.The therapeutic effect and side effects were observed.Results After 4weeks′treatment,the total effective rate of tumor size reduction was 80%in group B,and 72%in group A,there had no significant difference (P>0.05).AFP in group A was lower than group B (P<0.05).In side effects,the liver function damage in group A was lighter than group B,there was obvious difference between the 2 groups (P<0.05).Conclusion Microcatheter superseletive chemoebolization therapy for primary liver cancer has better efficacy and lighter side effect,it is worthy of clinical application.